Navigation Links
Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
Date:5/17/2011

GREENWOOD VILLAGE, Colo., May 17, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE)("Ampio" or the "Company"), a clinical stage developer of new uses for previously approved drugs and new molecular entities ("NMEs"), announces that its common stock has been approved for listing on the NASDAQ Capital Market.  The shares are scheduled to trade under the ticker symbol "AMPE" and the Company understands that trading will commence on that market in the coming days.

"The Company is pleased to make the transition to NASDAQ and raise our profile in the investment community," commented Don Wingerter, Ampio's chief executive officer. "We believe being listed on the Nasdaq Capital Market will provide Ampio with greater visibility, additional liquidity for our common stock, and opportunities to expand our investor base." Pending the listing change, Ampio's common stock will continue to trade on the OTC Bulletin Board.  

About Ampio

The company is currently performing a phase II clinical trial for the treatment diabetic macular edema and is evaluating the data from a recently completed phase III clinical trial for the treatment of premature ejaculation. Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include our expectation of commencing trading on the Nasdaq Capital Market in a timely manner. Forward-looking statements involve risks and uncertainties, such as unexpected delays in the listing process, changes in business conditions, and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.


Contact:
Investor Relations
Ampio Pharmaceuticals, Inc.
303-418-1000


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... /PRNewswire/ - Demers Ambulances announces its first delivery in the state ... County Emergency Medical Services (EMS) consisting of four ... van. Quality Emergency Vehicles in Lecanto, FL ... This is the latest in Demers, ongoing expansion of sales.  ... Demers. --> Benoit LaFortune , Executive Vice President ...
(Date:2/12/2016)... Feb. 12, 2016   HeartWare International, Inc . ... and webcast to discuss its financial results for the ... Thursday, February 25, 2016 at 8:00 a.m. ET.  The ... the conference call and webcast.  On the conference call ... highlights from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Tech Outlook’s top Clinical Data Management Solution Providers list for its expertise in ... functional and domain expertise to serve the technology needs of global clients. DDi ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan ... The purpose of these scholarships is to encourage applicants to pursue a degree in ... within these two parishes. , “We have available jobs in St. Landry and ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
Breaking Medicine News(10 mins):